Notice of Meeting: National Intelligence University Board of Visitors, 71889-71890 [2023-22967]
Download as PDF
<![CDATA[
71889
Federal Register / Vol. 88, No. 200 / Wednesday, October 18, 2023 / Notices
Controlled substance
Drug code
ddrumheller on DSK120RN23PROD with NOTICES1
ortho-Fluoroisobutyryl fentanyl (N-(2-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)isobutyramide) ...................................
Para-Fluoro furanyl fentanyl (N-(4-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)furan-2-carboxamide) ............................
2′-Fluoro ortho-fluorofentanyl (N-(1-(2- fluorophenethyl)piperidin-4-yl)-N-(2- fluorophenyl)propionamide; also known
as 2′-fluoro 2- fluorofentanyl).
beta-Methyl fentanyl (N-phenyl-N-(1-(2- phenylpropyl)piperidin-4-yl)propionamide; also known as b-methyl fentanyl) ..
Amphetamine .....................................................................................................................................................................
Methamphetamine .............................................................................................................................................................
Lisdexamfetamine ..............................................................................................................................................................
Phenmetrazine ...................................................................................................................................................................
Methylphenidate .................................................................................................................................................................
Amobarbital ........................................................................................................................................................................
Pentobarbital ......................................................................................................................................................................
Secobarbital .......................................................................................................................................................................
Glutethimide .......................................................................................................................................................................
1-Phenylcyclohexylamine ..................................................................................................................................................
Phencyclidine .....................................................................................................................................................................
ANPP (4-Anilino-N-phenethyl-4-piperidine) .......................................................................................................................
Norfentanyl (N-phenyl-N-(piperidin-4-yl) propionamide) ....................................................................................................
Phenylacetone ...................................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile ..................................................................................................................................
Cocaine ..............................................................................................................................................................................
Codeine ..............................................................................................................................................................................
Etorphine HCl ....................................................................................................................................................................
Dihydrocodeine ..................................................................................................................................................................
Oxycodone .........................................................................................................................................................................
Hydromorphone .................................................................................................................................................................
Ecgonine ............................................................................................................................................................................
Ethylmorphine ....................................................................................................................................................................
Hydrocodone ......................................................................................................................................................................
Levomethorphan ................................................................................................................................................................
Levorphanol .......................................................................................................................................................................
Isomethadone ....................................................................................................................................................................
Meperidine .........................................................................................................................................................................
Meperidine intermediate-B .................................................................................................................................................
Oliceridine (N-[(3-methoxythiophen-2yl)methyl] ({2-[9r)-9-(pyridin-2-yl)-6-oxaspiro[4.5] decan-9-yl] ethyl {time})amine
fumarate).
Methadone .........................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) ................................................................................................................
Morphine ............................................................................................................................................................................
Thebaine ............................................................................................................................................................................
Oxymorphone ....................................................................................................................................................................
Noroxymorphone ...............................................................................................................................................................
Thiafentanil ........................................................................................................................................................................
Alfentanil ............................................................................................................................................................................
Remifentanil .......................................................................................................................................................................
Sufentanil ...........................................................................................................................................................................
Carfentanil ..........................................................................................................................................................................
Tapentadol .........................................................................................................................................................................
Fentanyl .............................................................................................................................................................................
The company plans to bulk
manufacture the listed controlled
substances for forensic purposes, to
research analytical reference standards
and as Active Pharmaceutical
Ingredients for Phase 1 trials. In
reference to drug codes 7360
(Marihuana), and 7370
(Tetrahydrocannabinols), the company
plans to bulk manufacture these drugs
as synthetic. No other activities for these
drug codes are authorized for this
registration.
OFFICE OF THE DIRECTOR OF
NATIONAL INTELLIGENCE
Claude Redd,
Acting Deputy Assistant Administrator.
SUMMARY:
[FR Doc. 2023–22954 Filed 10–17–23; 8:45 am]
BILLING CODE P
VerDate Sep<11>2014
18:01 Oct 17, 2023
Jkt 262001
Notice of Meeting: National Intelligence
University Board of Visitors
National Intelligence
University (NIU), Office of the Director
of National Intelligence (ODNI).
ACTION: Notice of Federal advisory
committee meeting of the National
Intelligence University Board of
Visitors.
AGENCY:
ODNI is publishing this
notice to announce that the following
Federal advisory committee meeting of
the NIU Board of Visitors (BoV) will
take place. This meeting is closed to the
public.
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
Schedule
9853
9854
9855
I
I
I
9856
1100
1105
1205
1631
1724
2125
2270
2315
2550
7460
7471
8333
8366
8501
8603
9041
9050
9059
9120
9143
9150
9180
9190
9193
9210
9220
9226
9230
9233
9245
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
9250
9273
9300
9333
9652
9668
9729
9737
9739
9740
9743
9780
9801
II
II
II
II
II
II
II
II
II
II
II
II
II
Wednesday, 25 October, 2023,
8:30 a.m. to 3:00 p.m., and Thursday, 26
October, 8:30 a.m. to 1 p.m., Bethesda,
MD.
ADDRESSES: National Intelligence
University, 4600 Sangamore Road,
Bethesda, MD 20816.
FOR FURTHER INFORMATION CONTACT: Ms.
Patricia ‘‘Patty’’ Larsen, Designated
Federal Officer, (301) 243–2118 (Voice),
excom@odni.gov (email). Mailing
address is National Intelligence
University, Roberdeau Hall,
Washington, DC 20511. Website: https://
ni-u.edu/wp/about-niu/leadership-2/
board-of-visitors/.
SUPPLEMENTARY INFORMATION: This
meeting is being held under the
provisions of the Federal Advisory
DATES:
E:\FR\FM\18OCN1.SGM
18OCN1
71890
Federal Register / Vol. 88, No. 200 / Wednesday, October 18, 2023 / Notices
Committee Act of 1972 (5 U.S.C. 1001–
1014), the Government in the Sunshine
Act of 1976 (5 U.S.C. 552b), and 41 CFR
102–3.140 and 102–3.150. The meeting
includes the discussion of classified
information and classified materials
regarding intelligence education issues,
internal personnel rules and practices of
NIU, and pre-decisional strategic
planning matters; and the Director of
National Intelligence, or her designee, in
consultation with the ODNI Office of
General Counsel, has determined the
meeting will be closed to the public
under the exemptions set forth in 5
U.S.C. 552b(c)(1),552b(c)(2), and
552b(c)(9)(B).
I. Purpose of the Meeting: The Board
will discuss and provide written
observations and recommendations on
matters relating to NIU personnel,
budget, facilities, strategic planning,
information technology, intelligence
programs, subcommittee read-outs, and
whole of institution assessment data, as
well as discuss current classified
intelligence education issues.
II. Agenda: Welcome and Call to
Order; President State of the University;
Resources—Strategic Planning; Break
for Lunch; Resources—Budget,
Information Technology, Personnel,
Whole of Institution Assessment Data
(End of Day 1). Welcome and Call to
Order; Subcommittee Preparatory and
Administrative Meetings; Governance
and Strategic Planning Subcommittee
Meeting; NIU Board of Visitors
Executive Session (End of Day 2).
III. Meeting Accessibility: The public
or interested organizations may submit
written statements to the NIU BoV about
its mission and functions. Written
statements may be submitted at any
time or in response to the stated agenda
of a planned meeting of the NIU BoV.
IV. Written Statements: All written
statements shall be submitted to the
Designated Federal Officer for the NIU
BoV, and this individual will ensure
that the written statements are provided
to the membership for their
consideration.
Robert A. Newton,
Committee Management Officer and Deputy
Chief Operating Officer.
[FR Doc. 2023–22967 Filed 10–17–23; 8:45 am]
ddrumheller on DSK120RN23PROD with NOTICES1
BILLING CODE P
NEIGHBORHOOD REINVESTMENT
CORPORATION
Sunshine Act Meetings
2 p.m., Thursday,
October 19, 2023.
TIME AND DATE:
VerDate Sep<11>2014
18:01 Oct 17, 2023
Jkt 262001
1255 Union Street NE, Suite 500,
Washington, DC 20002.
STATUS: Parts of this meeting will be
open to the public. The rest of the
meeting will be closed to the public.
MATTERS TO BE CONSIDERED: Regular
Board of Directors meeting.
The Interim General Counsel of the
Corporation has certified that in her
opinion, one or more of the exemptions
set forth in the Government in the
Sunshine Act, 5 U.S.C. 552b(c)(2) and
(4) permit closure of the following
portion(s) of this meeting:
• Executive (Closed) Session
PLACE:
Agenda
I. Call to Order
II. Sunshine Act Approval of Executive
(Closed) Session
III. Executive Session: Report from CEO
IV. Executive Session: Report from CFO
V. Executive Session: GAO Workplan
Update
VI. Executive Session: Report from
Interim General Counsel
VII. Executive Session: Report from CIO
VIII. Executive Session: NeighborWorks
Compass Update
IX. Action Item: Approval of Meeting
Minutes—August 3 Special Audit
Committee Meeting and August 17
Annual Board of Directors Meeting
X. Action Item: Professional Learning
and Event Management System
(PLEMS)
XI. Action Item: Atlanta Office Lease
XII. Discussion Item: October 2 Audit
Committee Meeting
XIII. Discussion Item: National
NeighborWorks Association
Presentation
XIV. Discussion Item: Capital
Corporations Leadership
a. Community Housing Capital
b. NeighborWorks Capital
XV. Inflation Reduction Act Update
XVI. FY2024 Corporate Scorecard
XVII. Management Program Background
and Updates Other Reports
a. 2023 Board Calendar
b. 2023 Board Agenda Planner
c. CFO Report
i. Financials (through 7/31/23)
ii. Single Invoice Approvals $100K
and over
iii. Vendor Payments $350K and over
iv. Exceptions
d. Programs Dashboard
e. Housing Stability Counseling
Program (HSCP)
f. Strategic Plan Scorecard—FY23 Q3
(Q3 Production)
PORTIONS OPEN TO THE PUBLIC:
Everything except the Executive
(Closed) Session.
PORTIONS CLOSED TO THE PUBLIC:
Executive (Closed) Session.
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
CONTACT PERSON FOR MORE INFORMATION:
Jenna Sylvester, Paralegal, (202) 568–
2560; jsylvester@nw.org.
Jenna Sylvester,
Paralegal.
[FR Doc. 2023–23046 Filed 10–16–23; 11:15 am]
BILLING CODE P
POSTAL REGULATORY COMMISSION
[Docket Nos. MC2024–7 and CP2024–7;
MC2024–8 and CP2024–8; MC2024–9 and
CP2024–9; MC2024–10 and CP2024–10]
New Postal Products
Postal Regulatory Commission.
Notice.
AGENCY:
ACTION:
The Commission is noticing a
recent Postal Service filing for the
Commission’s consideration concerning
a negotiated service agreement. This
notice informs the public of the filing,
invites public comment, and takes other
administrative steps.
DATES: Comments are due: October 20,
2023.
ADDRESSES: Submit comments
electronically via the Commission’s
Filing Online system at https://
www.prc.gov. Those who cannot submit
comments electronically should contact
the person identified in the FOR FURTHER
INFORMATION CONTACT section by
telephone for advice on filing
alternatives.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
David A. Trissell, General Counsel, at
202–789–6820.
SUPPLEMENTARY INFORMATION:
Table of Contents
I. Introduction
II. Docketed Proceeding(s)
I. Introduction
The Commission gives notice that the
Postal Service filed request(s) for the
Commission to consider matters related
to negotiated service agreement(s). The
request(s) may propose the addition or
removal of a negotiated service
agreement from the Market Dominant or
the Competitive product list, or the
modification of an existing product
currently appearing on the Market
Dominant or the Competitive product
list.
Section II identifies the docket
number(s) associated with each Postal
Service request, the title of each Postal
Service request, the request’s acceptance
date, and the authority cited by the
Postal Service for each request. For each
request, the Commission appoints an
officer of the Commission to represent
E:\FR\FM\18OCN1.SGM
18OCN1
]]>Agencies
[Federal Register Volume 88, Number 200 (Wednesday, October 18, 2023)]
[Notices]
[Pages 71889-71890]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-22967]
=======================================================================
-----------------------------------------------------------------------
OFFICE OF THE DIRECTOR OF NATIONAL INTELLIGENCE
Notice of Meeting: National Intelligence University Board of
Visitors
AGENCY: National Intelligence University (NIU), Office of the Director
of National Intelligence (ODNI).
ACTION: Notice of Federal advisory committee meeting of the National
Intelligence University Board of Visitors.
-----------------------------------------------------------------------
SUMMARY: ODNI is publishing this notice to announce that the following
Federal advisory committee meeting of the NIU Board of Visitors (BoV)
will take place. This meeting is closed to the public.
DATES: Wednesday, 25 October, 2023, 8:30 a.m. to 3:00 p.m., and
Thursday, 26 October, 8:30 a.m. to 1 p.m., Bethesda, MD.
ADDRESSES: National Intelligence University, 4600 Sangamore Road,
Bethesda, MD 20816.
FOR FURTHER INFORMATION CONTACT: Ms. Patricia ``Patty'' Larsen,
Designated Federal Officer, (301) 243-2118 (Voice), [email protected]
(email). Mailing address is National Intelligence University, Roberdeau
Hall, Washington, DC 20511. Website: https://ni-u.edu/wp/about-niu/leadership-2/board-of-visitors/.
SUPPLEMENTARY INFORMATION: This meeting is being held under the
provisions of the Federal Advisory
[[Page 71890]]
Committee Act of 1972 (5 U.S.C. 1001-1014), the Government in the
Sunshine Act of 1976 (5 U.S.C. 552b), and 41 CFR 102-3.140 and 102-
3.150. The meeting includes the discussion of classified information
and classified materials regarding intelligence education issues,
internal personnel rules and practices of NIU, and pre-decisional
strategic planning matters; and the Director of National Intelligence,
or her designee, in consultation with the ODNI Office of General
Counsel, has determined the meeting will be closed to the public under
the exemptions set forth in 5 U.S.C. 552b(c)(1),552b(c)(2), and
552b(c)(9)(B).
I. Purpose of the Meeting: The Board will discuss and provide
written observations and recommendations on matters relating to NIU
personnel, budget, facilities, strategic planning, information
technology, intelligence programs, subcommittee read-outs, and whole of
institution assessment data, as well as discuss current classified
intelligence education issues.
II. Agenda: Welcome and Call to Order; President State of the
University; Resources--Strategic Planning; Break for Lunch; Resources--
Budget, Information Technology, Personnel, Whole of Institution
Assessment Data (End of Day 1). Welcome and Call to Order; Subcommittee
Preparatory and Administrative Meetings; Governance and Strategic
Planning Subcommittee Meeting; NIU Board of Visitors Executive Session
(End of Day 2).
III. Meeting Accessibility: The public or interested organizations
may submit written statements to the NIU BoV about its mission and
functions. Written statements may be submitted at any time or in
response to the stated agenda of a planned meeting of the NIU BoV.
IV. Written Statements: All written statements shall be submitted
to the Designated Federal Officer for the NIU BoV, and this individual
will ensure that the written statements are provided to the membership
for their consideration.
Robert A. Newton,
Committee Management Officer and Deputy Chief Operating Officer.
[FR Doc. 2023-22967 Filed 10-17-23; 8:45 am]
BILLING CODE P
